Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP2C19 genotype-guided P2Y12 inhibitor selection in oral anticoagulation-treated patients undergoing PCI
NL-OMON52157Recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of clopidogrel, ticagrelor and aspirin in coronary arteriosclerosis, sponsored by Erasmus MC. Primary endpoints: Primary safety endpoint and Primary efficacy endpoint. Started Apr 2023; status: recruiting.
02
Drugs
clopidogrelticagreloraspirin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON52157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52157.